targeted therapy resistance mediated dynamic regulation extrachromosomal mutant egfr dna
intratumoral heterogeneity contributes cancer drug resistance underlying mechanisms understood single-cell analyses patient-derived models clinical samples glioblastoma patients treated epidermal growth factor receptor egfr tyrosine kinase inhibitors tkis demonstrate tumor cells reversibly up-regulate suppress mutant egfr expression conferring distinct cellular phenotypes reach optimal equilibrium growth resistance egfr tkis shown occur elimination mutant egfr extrachromosomal dna drug withdrawal reemergence clonal egfr mutations extrachromosomal dna follows results indicate highly specific dynamic adaptive route cancers can evade therapies target oncogenes maintained extrachromosomal dna
